Abemaciclib plus trastuzumab fulvestrant increased OS for HR+, HER2+ advanced breast cancer

Bookmark and Share
Published: 21 Sep 2022
Views: 46
Dr Sara Tolaney - Dana-Farber Cancer Institute, Boston, USA

Dr Sara Tolaney speaks to ecancer about monarcHER, a randomised phase 2 trial, which looked at the final overall survival data for abemaciclib plus trastuzumab fulvestrant versus trastuzumab plus chemotherapy in HR+, HER2+ advanced breast cancer.

She explains the results showed abemaciclib plus trastuzumab fulvestrant numerically improved OS in 669 women with HR+, HER2+ ABC compared to chemotherapy plus trastuzumab with a manageable safety profile.

Dr Tolaney also outlines some of the potential current and future treatment options for breast cancer patients.